Taxanes in lung cancer: a review with focus on the European experience

✍ Scribed by Antonello Calderoni; Thomas Cerny

• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 192 KB
• Volume: 38
• Category: Article
• ISSN: 1040-8428
• DOI: 10.1016/s1040-8428(00)00121-9

✦ Synopsis

The introduction of new agents in the treatment of lung cancer raised in the past few years new interest in clinical research on this topic. The use of taxanes as paclitaxel and docetaxel may represent a significant progress in the treatment of lung cancer. Taxanes used as single agents show a substantial activity in lung cancer and, because of their unique mechanism of action, it is possible to combine these drugs with other non-cross-resistant agents. Taxanes share a radiosensitizing effect and their use with concurrent radiotherapy appears to become a new standard. This review will focus on the European clinical experience in the treatment of lung cancer with the two compounds.